Clinical trial · Interventional
Cognition in the Study of Tamoxifen and Raloxifene
Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene
NCT00687102CI-TRIAL-00034821Co-STARcompletedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aging | — | UNRESOLVED | — |
| Cognition | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| raloxifene | Drug | — | UNRESOLVED |
| tamoxifen | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Star participants assigned to Tamoxifen
- description
- Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
- interventionNames
- Drug: tamoxifen
- type
- EXPERIMENTAL
- label
- Star participants assigned to Raloxifene
- description
- Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
- interventionNames
- Drug: raloxifene
Primary outcomes (2)
- measure
- Mean Change From Baseline on the the Benton Visual Retention Test Scores by Treatment Group
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Women enrolled in STAR trial at a site participating in Co-STAR * 65 years of age or older * Have been randomized into STAR but have not started taking the study drug OR enrolled in STAR for a minimum of one year * Have not been diagnosed with dementia * Have signed a separate consent document for the Co-STAR Study * Previous diagnoses of chronic neurologic disease (Parkinson's disease, stroke, epilepsy, multiple sclerosis), history of head injury, depression, alcohol addiction, drug addiction, and other neurologic or psychiatric conditions will be recorded but will not serve as exclusion factors for this study Exclusion Criteria: * Not enrolled in the STAR Trial * Younger than 65 years of age * Diagnosed with dementia
References
Publications (3)
- BACKGROUNDMaki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry. 2001 Feb;158(2):227-33. doi: 10.1176/appi.ajp.158.2.227. PMID 11156805
- BACKGROUNDResnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology. 1997 Dec;49(6):1491-7. doi: 10.1212/wnl.49.6.1491. PMID 9409335
- BACKGROUNDResnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 1998 Oct;34(2):171-82. doi: 10.1006/hbeh.1998.1476. PMID 9799627